Pfizer Q3 preview: Where next for the Pfizer share price?

Pfizer’s revenue and earnings have soared thanks to strong demand for its coronavirus vaccine, but there are concerns there could be a significant slowdown in 2022. We explain what to expect and consider how Pfizer shares could react.

Charts (2)

When will Pfizer release Q3 earnings?

Pfizer is scheduled to release third quarter earnings on Tuesday November 2.

 

Pfizer Q3 earnings preview: what to expect from the results

The Covid-19 vaccine developed by Pfizer, as well as its German partner BioNTech, has transformed the business this year. Pfizer is set to ship 2.1 billion doses of its jabs – one of the most widely-used around the world - this year and reap a staggering $33.5 billion in sales. For context, the rest of Pfizer’s wider business is forecast to generate sales of $44.5 to $46.5 billion.

As orders for the vaccine continue to flood-in, Pfizer has upgraded its guidance on several occasions this year. When it made the last upgrade back in July, it said it is targeting annual 2021 revenue of between $78.0 billion to $80.0 billion with adjusted EPS of $3.95 to $4.05. If achieved, that would deliver impressive growth from the $41.9 billion in revenue and EPS of $2.22 booked in 2020.

Notably, analysts believe Pfizer can beat that guidance with consensus numbers from Bloomberg showing Wall Street is forecasting Pfizer will deliver annual revenue of $81.0 billion and EPS of $4.11, prompted by strong demand for its vaccine. This is a signal in itself that Pfizer could upgrade expectations once again when it releases third quarter earnings.

Wall Street is expecting Pfizer to report revenue of $22.71 billion in the third quarter. That would be up 87% from the $12.13 billion in sales booked the year before, marking a slight acceleration in topline growth from the 86% year-on-year rise reported in the last quarter.

Adjusted EPS is forecast to increase to $1.09 from $0.72 with reported EPS expected to jump to $1.03 from just $0.39 the year before.

There seems little doubt that 2021 will be a blowout year for Pfizer, with demand for its vaccine poised to almost double overall revenue. However, analysts are far more uncertain going into 2022. Vaccine sale estimates for 2022 are wide-ranging, from as low as $9 billion to as high as $34 billion, according to numbers from Bloomberg. The reason for the large gap between forecasts is largely down to the uncertainty over how developed nations will use booster shots going forward and because more sales will shift to lower-and-middle-income countries, where the economics may different. Markets would welcome any update that could allay concerns over vaccine sales next year, although they may have to wait for the fourth quarter earnings to get a full picture.

Pfizer shares are currently trading over 24% higher than pre-pandemic levels but have lost steam since hitting fresh all-time highs in August. The 22 brokers covering the stock currently have a Hold rating on Pfizer but the average target price of $46.45 implies there is over 8% potential upside from the current share price.

 

Where next for the Pfizer share price?

The Pfizer share price steadily trended higher across the year accelerating the runup to $51.86, the all-time high hit in mid-August. The price then trended lower finding support at $41. 

The price is extending its rebound from $41, the 3-month low, and is attempting to retake the ascending trendline dating back to early March. 

Buyers will be looking for a move over $44 the monthly high and $44.50 the 50 sma in order for bulls to gain traction. 

Meanwhile, sellers are looking for a move below $41 which would expose the 200 sma at $40. Beyond here, the stock could eye $38.50. 

Where next for the Pfizer share price?

 

How to trade Pfizer shares

You can trade Pfizer shares with City Index in just four easy steps:

  1. Open a City Index account, or log-in if you’re already a customer.
  2. Search for ‘Pfizer’ in our award-winning platform
  3. Choose your position and size, and your stop and limit levels
  4. Place the trade

 

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.